Meiji Yasuda Asset Management Co Ltd. Invests $3.57 Million in Insulet Corporation $PODD

Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,461 shares of the medical instruments supplier’s stock, valued at approximately $3,572,000.

A number of other hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Insulet in the 2nd quarter worth about $1,018,582,000. Norges Bank purchased a new stake in Insulet in the 4th quarter valued at about $300,794,000. Arrowstreet Capital Limited Partnership grew its stake in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after acquiring an additional 1,011,369 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Insulet in the 2nd quarter worth about $60,615,000. Finally, Deutsche Bank AG bought a new position in Insulet in the 2nd quarter worth about $51,153,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: CEO Ashley McEvoy purchased 1,100 Insulet shares at an average price of $147.47, an investment of approximately $162,200. The transaction increased her direct holdings by about 5% and may signal management confidence after the stock’s substantial decline. Insulet CEO share purchase article
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Levi & Korsinsky, and others—are soliciting investors who purchased PODD securities during periods generally spanning February 21, 2025, through May 26, 2026. Investors have until August 31, 2026, to seek appointment as lead plaintiff. These announcements largely repeat existing litigation information rather than represent new operating developments. Rosen Law Firm Insulet deadline article
• Negative Sentiment: The lawsuit-related releases allege that Insulet and certain officers violated federal securities laws by failing to disclose issues associated with two voluntary Medical Device Corrections involving Omnipod insulin-delivery systems. The allegations reportedly concern systemic manufacturing defects and potential investor losses; they have not been proven in court. Continued legal publicity increases regulatory, financial, and reputational uncertainty for Insulet and is likely the main reason investor sentiment remains weak. Levi and Korsinsky Insulet class action article

Insider Activity

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Insulet Price Performance

NASDAQ PODD opened at $145.42 on Tuesday. The company has a market cap of $10.08 billion, a PE ratio of 27.18, a P/E/G ratio of 1.17 and a beta of 1.10. The firm’s 50 day moving average price is $154.61 and its 200-day moving average price is $183.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. Insulet’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PODD has been the subject of several research analyst reports. Robert W. Baird set a $175.00 price target on shares of Insulet in a research note on Thursday, August 6th. Weiss Ratings cut Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. BTIG Research downgraded Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Citigroup lifted their target price on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, Barclays lowered their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $195.40.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.